Transcriptional profiling and network pharmacology analysis identify the potential biomarkers from Chinese herbal formula Huosu Yangwei Formula treated gastric cancer in vivo.
10.1016/S1875-5364(22)60154-7
- Author:
Sheng-Quan FANG
1
;
Yue-Han LIU
2
;
Kun-Peng ZHAO
2
;
Hui-Xing ZHANG
3
;
Hong-Wei WANG
1
;
Yu-Hai DENG
1
;
Yu-Xuan ZHOU
1
;
Guang-Bo GE
2
;
Hong-Mei NI
4
;
Qi-Long CHEN
5
,
6
Author Information
1. Department of Gastroenterology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China.
2. Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
3. School of Basic Medical Science, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
4. School of Basic Medical Science, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China. Electronic address: nihm20032003@163.com.
5. Department of Gastroenterology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China
6. Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China. Electronic address: cqlw1975@126.com.
- Publication Type:Journal Article
- Keywords:
Gastric Cancer;
Huosu Yangwei (HSYW) Formula;
Network pharmacology;
Protein-protein interaction (PPI) network
- MeSH:
Animals;
Biomarkers;
China;
Drugs, Chinese Herbal;
Mice;
Network Pharmacology;
Stomach Neoplasms/genetics*
- From:
Chinese Journal of Natural Medicines (English Ed.)
2021;19(12):944-953
- CountryChina
- Language:English
-
Abstract:
Huosu Yangwei (HSYW) Formula is a traditioanl Chinese herbal medicine that has been extensively used to treat chronic atrophic gastritis, precancerous lesions of gastric cancer and advanced gastric cancer. However, the effective compounds of HSYW and its related anti-tumor mechanisms are not completely understood. In the current study, 160 ingredients of HSYW were identified and 64 effective compounds were screened by the ADMET evaluation. Furthermore, 64 effective compounds and 2579 potential targets were mapped based on public databases. Animal experiments demonstrated that HSYW significantly inhibited tumor growth in vivo. Transcriptional profiles revealed that 81 mRNAs were differentially expressed in HSYW-treated N87-bearing Balb/c mice. Network pharmacology and PPI network showed that 12 core genes acted as potential markers to evaluate the curative effects of HSYW. Bioinformatics and qRT-PCR results suggested that HSYW might regulate the mRNA expression of DNAJB4, CALD, AKR1C1, CST1, CASP1, PREX1, SOCS3 and PRDM1 against tumor growth in N87-bearing Balb/c mice.
